Ozempic: From Diabetes Treatment to Weight-Loss Craze in the US

The Rise of GLP-1 Agonists

• 💡 Originally developed for type 2 diabetes, GLP-1 drugs like Ozempic, WGOI, and Mjaro have seen a significant increase in use worldwide since their US launch in 2017.
• 🎯 These medications are now frequently repurposed by non-diabetics seeking to lose weight due to their appetite-suppressing effects.

Impact on Eating Habits and Society

• 🍽️ In the US, the appetite-suppressing effects are noticeable, with some restaurants even acknowledging the trend, like a New York bar that decorated a small burger with a plastic syringe of ketchup.
• 📉 A self-described foodie reported losing 9 kg in 2 months, attributing it to the drug's effect on her appetite, alongside increased protein intake, reduced alcohol consumption, and more physical activity.
• ⚠️ The speaker observed people eating significantly less, leading to a considerable amount of food waste.

Expanding Access to Treatment

• 💉 While traditionally administered via injection, a new oral GLP-1 drug was recently approved in the US.
• 🚀 This oral option is expected to broaden access to these treatments for a larger population of Americans.